Last Posted: Jan 31, 2019
- Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.
Greden John F et al. Journal of psychiatric research 2019 Jan 11159-67 - An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care.
Sluiter Reinier L et al. The pharmacogenomics journal 2019 Jan - Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study.
McCuaig Jeanna M et al. Gynecologic oncology 2019 Jan - Genetic associations with suicide attempt severity and genetic overlap with major depression.
Levey Daniel F et al. Translational psychiatry 2019 Jan 9(1) 22 - A Systematic Review of the Psychological Implications of Genetic Testing: A Comparative Analysis Among Cardiovascular, Neurodegenerative and Cancer Diseases.
Oliveri Serena et al. Frontiers in genetics 2018 9624 - Huge trove of British biodata is unlocking secrets of depression, sexual orientation, and more
J Kaiser et al, Science, January 3, 2019 - Polygenic risk score identifies associations between sleep duration and diseases determined from an electronic medical record biobank.
Dashti Hassan S et al. Sleep 2018 Dec - A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial.
Han Changsu et al. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology 2018 Nov 16(4) 469-480 - Statistical pitfalls of personalized medicine
S Senn, Nature News, November 27, 2018 - Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multi-center COGENT Study.
Beri Nina et al. Clinical genetics 2018 Nov
.png)
No hay comentarios:
Publicar un comentario